120145-22-4

Usage

Uses

2-Chloro-6-Isopropylpyridine is used as a chemical intermediate in the synthesis of various compounds, particularly in the pharmaceutical and agrochemical industries. Its unique structure and reactivity make it a valuable building block for the development of new drugs and agrochemicals.
Used in Pharmaceutical Industry:
2-Chloro-6-Isopropylpyridine is used as a key intermediate for the synthesis of pharmaceutical compounds, contributing to the development of new medications with potential therapeutic applications.
Used in Agrochemical Industry:
2-Chloro-6-Isopropylpyridine is used as a precursor in the production of agrochemicals, such as pesticides and herbicides, to improve crop protection and yield. Its role in these applications is to provide a stable and reactive platform for the attachment of functional groups that enhance the effectiveness of the final product.

InChI:InChI=1/C8H10ClN/c1-6(2)7-4-3-5-8(9)10-7/h3-6H,1-2H3

Upstream product

• 18368-63-3 6-chloro-2-picoline 
• 1184955-13-2 2-tert-butoxy-6-isopropylpyridine 
• 75-30-9 2-iodo-propane 

Downstream Products

• 1184955-18-7 diphenyl[6-(isopropyl)-2-pyridyl]phosphine 

Relevant academic research and scientific papers

Radical chain monoalkylation of pyridines

The monoalkylation of N-methoxypyridinium salts with alkyl radicals generated from alkenes (via hydroboration with catecholborane), alkyl iodides (via iodine atom transfer) and xanthates is reported. The reaction proceeds under neutral conditions since no acid is needed to activate the heterocycle and no external oxidant is required. A rate constant for the addition of a primary radical to N-methoxylepidinium >107 M-1 s-1 was experimentally determined. This rate constant is more than one order of magnitude larger than the one measured for the addition of primary alkyl radicals to protonated lepidine demonstrating the remarkable reactivity of methoxypyridinium salts towards radicals. The reaction has been used for the preparation of unique pyridinylated terpenoids and was extended to a three-component carbopyridinylation of electron-rich alkenes including enol esters, enol ethers and enamides.

The AZARYPHOS family of ligands for ambifunctional catalysis: Syntheses and use in ruthenium-catalyzed anti-markovnikov hydration of terminal alkynes

The family of AZARYPHOS (aza-aryl-phosphane) phosphane ligands, containing a phosphine unit and sterically shielded nitrogen lone pairs in the ligand periphery, is introduced as a tool for developing ambifunctional catalysis by the metal center and nitrogen lone pairs in the ligand sphere. General synthetic strategies have been developed to synthesize over 25 examples of structurally diverse (6-aryl-2pyridyl)phosphanes (ARPYPHOS), (6alkyl-2-pyridyl)phosphanes (ALPY-PHOS), 4,6-disubsituted l,3-diazin-2ylphosphanes or l,3,5-triazin-2- ylphosphanes, quinazolinylphosphanes, quinolinylphosphanes, and others. The scalable syntheses proceed in a few steps. The incorporation of AZARYPHOS ligands (L) into complexes [RuCp(L)2(MeCN)][PF6] (Cp = cyclopentadieny1)gives catalysts for the anti-Markovnikov hydration of terminal alkynes of the highest known activities. Electronic and steric ligand effects modulate the reaction kinetics over a range of two orders of magnitude. These results highlight the importance of using structurally diverse ligand families in the process of developing cooperative ambifunctional catalysis by a metal and its ligand.

6-Alkyl-N,N-disubstituted-2-pyridinamines as anticonvulsant agents

The anticonvulsant effect of a series of 6-alkyl-N,N-disubstituted-2-pyridinamines is described. An investigation was carried out to optimize the anticonvulsant activity and reduce behavioral side effects in this series. Three compounds (7, 8, 10; Table I) were selected from initial screening for a more complete pharmacological evaluation. While each of these compounds was a potent anticonvulsant agent with ED50 values from 5 to 10 mg/kg, the activity was accompanied by significant behavioral side effects including decreased spontaneous locomotion, ataxia, and ptosis.